IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...

The Volta Regional Communication Bureau of the National Democratic Congress (NDC) has distributed a total of 200 smartphones to the party’s communicators. According to the Regional Communication ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

BANGKOK , Oct. 26, 2024 /PRNewswire/ -- LianLian Global has partnered with WeChat Pay to streamline the ticket purchasing process for visitors to Bangkok's Grand Palace. The collaboration leverages ...

GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...

Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...

Ipsen again raised its targets for 2024, now targeting an operating margin of over 31% of sales. GSK announced a single dose of Arexvy elicited robust immune response with acceptable safety profile in ...

“One factor that may help decrease the severity of this year’s RSV season is the availability of new RSV vaccines: Arexvy, Abrysvo, and mResvia,” Choudhury says. The CDC recommends one dose ...

US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...